Serum immunoreactive erythropoietin level: a new parameter for monitoring transfusion management of thalassaemia.
Serum immunoreactive erythropoietin (EPO) was measured sequentially in 8 patients with thalassaemia major. The EPO levels were distinctly increased before transfusion; they did not significantly change just after transfusion, but subsequently decreased. Pretransfusion EPO levels were similar to those observed in patients with non renal non inflammatory anaemias of the same severity. Our results show that production of EPO is appropriately increased in thalassaemia major and confirm that stimulation of endogenous erythropoiesis is not completely suppressed by the hypertransfusion regimen commonly used in this disease. As hyperstimulated ineffective erythropoiesis may lead to invalidating complications, we suggest that serum EPO measurements, which are now easily and reliably performed, should be used in monitoring the therapy of thalassaemia major.
André
M
M
Laboratory of Haematology, Hôpital Brugmann, Brussels, B-Belgium.
Bergmann
P
P
Ferster
A
A
Toppet
M
M
Fondu
P
P
D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood*; D001803:Blood Transfusion; D002648:Child; D004921:Erythropoietin / Q000097:blood* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D013789:Thalassemia / Q000097:blood* / Q000628:therapy
D015415:Biomarkers; D004921:Erythropoietin